18 min listen
Pharma Bro, Price Controls, and the Quest to Balance Innovation with Affordability
FromThe Bio Report
Pharma Bro, Price Controls, and the Quest to Balance Innovation with Affordability
FromThe Bio Report
ratings:
Length:
27 minutes
Released:
Feb 25, 2016
Format:
Podcast episode
Description
The embattled pharma executive Martin Shkreli, whether intentional or not, has ignited a long smoldering public policy discussion about the pricing of pharmaceuticals. As there are growing calls for steps to restrain drug prices, there are also industry concerns about the effect such actions would have on the ability to attract investment and pursue the development of high-risk, innovative therapies. We spoke to Denis Corin, CEO of Q BioMed, an acceleration and development company, for a perspective on the fallout from Shkreli, how to balance innovation with affordability, and whether he expects any lasting impacts on small drug developers.
Released:
Feb 25, 2016
Format:
Podcast episode
Titles in the series (100)
Epirus Sees Opportunities for Biosimilars Outside U.S.: The regulatory pathway for biosimilars is still a work in progress at the U.S. Food and Drug Administration, but around the world the industry is growing as regulators have resolved issues that remain obstacles in the United States. We spoke to Amit ... by The Bio Report